Journal article

Screening and Prophylaxis to Prevent Hepatitis B Reactivation Other Populations and Newer Agents

Joe Sasadeusz, Andrew Grigg, Peter D Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G Gish, Kumar Visvanathan

Clinics in Liver Disease | W B SAUNDERS CO-ELSEVIER INC | Published : 2019

Abstract

Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.